BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

Passage Bio’s frontotemporal dementia gene therapyUniversity of Pennsylvania spinout Passage Bio Inc. reported that administration of PBFT02, an AAV1-GRN vector, led to elevated levels of PGRN in the brain and cerebral spinal fluid (CSF), reduced lysosomal...
BioCentury | Sep 5, 2020
Deals

Deal with AbbVie, PIPE triples I-Mab’s cash, positions biotech to be among China’s CD47 leaders

Immuno-oncology company I-Mab nearly tripled its cash position on Friday, adding more than $600 million to its coffers through a CD47 licensing deal with AbbVie and a PIPE financing led by Hillhouse Capital. The deal...
BioCentury | Sep 2, 2020
Product Development

COVID-19 Quick Takes: NAS framework on vaccine allocation prioritizes higher risk groups

Framework to allocate vaccinesA discussion draft of a framework on equitable allocation of COVID-19 vaccines released by The National Academies of Sciences, Engineering and Medicine proposes...
BioCentury | Aug 6, 2020
Product Development

Warp Speed makes J&J COVID-19 vaccine program fifth above $1B

J&J’s manufacturing and delivery deal with HHS and DoD brings to $9.3 billion the amount Operation Warp Speed has committed to COVID-19 vaccines, $1.5 billion of which is now committed to the pharma. The deal...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

COO Franz-Werner Haas will become CureVac AG ’s permanent CEO, the mRNA vaccines company’s third this year. He has filled the role on an interim basis since mid-March. CEO Ingmar Hoerr took a leave of...
BioCentury | Aug 1, 2020
Tools & Techniques

A plasma tau marker gains support for diagnosing Alzheimer’s disease

Two studies published this week advance the search for blood tests for Alzheimer’s disease, but it’s not yet clear how transformative the plasma markers will be. Both studies came to the same conclusion: one form...
BioCentury | Jul 30, 2020
Product Development

Finding immunosuppression sweet spot could be next up for COVID-19 after second IL-6 failure

A Phase III miss for a second IL-6 inhibitor in COVID-19 patients could be the death knell for the drug class in the disease. But the mortality benefit demonstrated by dexamethasone suggests a broader immunosuppressive...
BioCentury | Jul 10, 2020
Product Development

Evive meets in Phase III for chemotherapy-induced neutropenia; plus regulatory updates for Biogen, Eisai, Merck, AZ

Evive planning BLA, MAA for neutropenia therapy following pivotal trial readout Evive Biotech Inc. said efbemalenograstim alfa met the primary and secondary endpoints in a Phase III study to prevent chemotherapy-induced neutropenia in breast cancer...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Biocryst’s galidesivir effective against Zika in macaques

DISEASE CATEGORY: Infectious disease INDICATION: Zika virus Biocryst’s broad-spectrum viral RNA polymerase inhibitor galidesivir could prevent and treat Zika virus infection. In rhesus macaques, galidesivir treatment starting 1.5 hours after subcutaneous infection reduced Zika virus...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

Breaking through the noise of poor-quality clinical studies are the first clear signals of a treatment paradigm for COVID-19, indicating how and when to use the two major therapeutic approaches -- attacking the virus and...
Items per page:
1 - 10 of 1937